Adenoid cystic carcinoma (ACC) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Indication name: Adenoid cystic carcinoma (ACC)

Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma, a type of cancer that begins in glandular tissues. It most commonly arises in the major and minor salivary glands of the head and neck. It can also occur in the breast, uterus, or other locations in the body.

Etiology-

The exact cause of adenoid cystic carcinoma is unknown.  New studies spaculate that a protein produced by the fusion of two transcription factor genes, MYB-NFIB, plays a role in the development of ACC tumors. This fusion protein is found in up to 90-95 % of ACC tumors. Mutations in the NOTCH1 gene are also associated with ACC, particularly in patients with recurrent or metastatic disease. Patients with NOTCH1 gene mutations have a worse prognosis.

Epidemiology-

Every year, about 1,200 individuals are diagnosed with ACC in the United States. 58% of ACC patients exhibit tumors in the oral cavity, salivary glands, and pharynx, 17% in the respiratory system, 12% in the breast, and the remaining 13% of tumors occur in other areas of the body such as on the skin, lacrimal glands, prostate, etc.

The competitive landscape of Adenoid cystic carcinoma (ACC) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Adenoid cystic carcinoma (ACC) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Adenoid cystic carcinoma (ACC) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Adenoid cystic carcinoma (ACC) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset                           Company                                 Stage

1          AL101                       Ayala Pharmaceuticals, Inc       Phase 2

2          Pembrolizumab         Dana-Farber Cancer Institute      Phase 2

3          Lenvatinib         Eisai Inc.          Phase 2

4          doxorubicin and bortezomib       Millennium Pharmaceuticals, Inc.            Phase 2

5          Regorafenib      Bayer   Phase 2

6          Dovitinib (TKI258)         Novartis Pharmaceuticals          Phase 2

7          AG-013736 (AXITINIB)  Pfizer    Phase 2

8          Lenalidomide, Everolimus          Celgene            Phase 1

9          CV8102            CureVac AG     Phase 1

10        Rivoceranib       Elevar Therapeutics       Phase 2

Continued...